ZDHHC20 Activates AKT Signaling Pathway to Promote Cell Proliferation in Hepatocellular Carcinoma
Xiaoju Huang,Mengmeng Wang,Dan Zhang,Junpeng Meng,Pian Liu
DOI: https://doi.org/10.2147/jhc.s457682
2024-09-19
Journal of Hepatocellular Carcinoma
Abstract:Xiaoju Huang, 1– 3 Mengmeng Wang, 1– 3 Dan Zhang, 1– 3 Junpeng Meng, 4, 5 Pian Liu 1– 3 1 Cancer Center Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, People's Republic of China; 3 Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 4 Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 5 Department of General Surgery, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China Correspondence: Pian Liu; Junpeng Meng, Email ; Background: Liver cancer is the sixth most common cancer worldwide, and hepatocellular carcinoma (HCC) presents one of the most challenging global health issues. ZDHHC20, a member of the ZDHHC palmitoyltransferase (ZDHHC-PAT) family, is involved in a reversible lipid modification known as palmitoylation, which contributes to the occurrence and progression of various tumors. However, the specific mechanisms underlying the involvement of ZDHHC20 in this process are unclear. Methods: The effects of both ZDHHC20 knockdown and overexpression on hepatocellular carcinoma cell proliferation were evaluated using PCR, Western blotting, CCK-8 assay, colony formation assay, cell cycle analysis, apoptosis analysis, and EDU assay. The TCGA-LIHC dataset was analyzed bioinformatically, and the phosphorylation level of PI3K and AKT in SK-Hep1 and Huh7 cells was assessed using Western blotting. Nude mouse subcutaneous xenograft experiments were conducted to evaluate the effects of different treatment conditions on mouse tumor growth. Results: ZDHHC20 knockdown inhibited cell proliferation and promoted apoptosis, while overexpression of ZDHHC20 promoted cell proliferation and inhibited apoptosis. Knockdown of ZDHHC20 also decreased phosphorylation of PI3K and AKT in HCC, whereas overexpression of ZDHHC20 increased phosphorylation of PI3K and AKT. The PI3K-AKT pathway inhibitors, LY294002 and MK2206, effectively inhibited the promotional effects of ZDHHC20 on the proliferation and growth of HCC. Conclusion: High expression of ZDHHC20 promotes the proliferation and tumor growth of HCC by activating the PI3K-AKT signaling pathway. The PI3K inhibitor LY294002 and the AKT inhibitor MK2206 inhibit the promotional effects of ZDHHC20 on the proliferation of HCC and the growth of tumors. Keywords: hepatocellular carcinoma, ZDHHC20, PI3K-AKT pathway, cell proliferation Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. According to 2020 statistics, liver cancer is the sixth most common cancer and the third leading cause of cancer-related death. 1 HCC accounts for approximately 75–85% of primary liver cancer. 2 Unfortunately, most cases of HCC are diagnosed late due to delayed symptoms and lack of early detection, resulting in poor prognosis for patients. Therefore, more in-depth investigation on the mechanisms underlying HCC occurrence, metastasis, and recurrence, as well as the exploration of appropriate targeted interventions, is needed to improve the prognosis for patients with HCC. Palmitoylation is a reversible lipid modification process in which palmitoyl groups are covalently bound by thioester bonds to cysteine by palmitoyl acyltransferase. 3,4 Palmitoylation is catalyzed primarily by the ZDHHC palmitoyl S-acyltransferases (PATs) family of proteins, which are known as DHHC-PAT because of their unique catalytic motif, DHHC (Asp-His-His-Cys). 5 This domain also combines two Zn2+ ions to form a zinc finger domain, resulting in a ZDHHC palmitoyltransferase. To date, 23 human ZDHHC genes (named ZDHHC1–24, without ZDHHC10) have been identified. 6 Although palmitoylation is known to regulate protein localization, stability, and function, the mechanisms by which ZDHHCs select substrate proteins for modification is not fully understood. ZDHHC20 is one of the most extensively studied members of this family and is the only DHHC enzyme with a known spatial structure. 7 Since the discovery of palmitoylation, various proteins have been found to undergo ZDHHC-mediated palmitoylation modification, which is implicated in the occurrence and development of various tumors. A list of 299 cancer driver genes was recently validated, of which 26% may undergo palmitoylation modification. 8 At least 15 of the 23 known human ZDHHCs a -Abstract Truncated-
oncology